Meeting Newsroom

Benefit of AlloSCT for Patients With TP53 Mutations and Acute Myeloid Leukemia/Myelodysplatic Syndromes
Koen W. van Besien, MD, recaps a debate in which he argued that patients with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) and TP53 mutations should undergo allogeneic stem cell transplantation.
Bispecific Antibodies, CAR T-Cell Therapy, and BCMA-Directed Therapy for the Treatment of Multiple Myeloma With Curative Intent
Sundar Jagannath, MD, provides an update on how immunotherapy and cellular therapy are changing treatment approaches for multiple myeloma.
How to Handle Challenging Management Issues in AML
Gail J. Roboz, MD, provides some key points to consider when handling challenging management issues in AML at the 2022 Lymphoma, Leukemia & Myeloma Congress in New York.

Questions?